It has been indicated that anti-CTLA-4 administration can potentiate the immune responses of NY-ESO-1 antigen-specific B cell and T cells through augmented production of MIP-1β, IFN-γ, and TNF-α in patients suffering from metastatic melanoma [138]. Here, CTLA4 is linked to metastatic melanoma.